Association of COVID-19 with Risk and Progression of Alzheimer’s Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects
Journal of Alzheimer's Disease · 2023
DOI: 10.3233/jad-230632 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, 2023. Verfasst von Pingjian Ding und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, OH, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, COVID-19. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCATS NIH HHS, NIAAA NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Background
Epidemiological studies showed that COVID-19 increases risk of Alzheimer’s disease (AD). However, it remains unknown if there is a potential genetic predispositional effect.
Objective
To examine potential effects of genetic susceptibility of COVID-19 on the risk and progression of AD, we performed a non-overlapping 2-sample Mendelian randomization (MR) study using summary statistics from genome-wide association studies (GWAS).
Methods
Two-sample Mendelian randomization (MR) analysis of over 2.6 million subjects was used to examine whether genetic susceptibility of COVID-19 is not associated with the risk of AD, cortical amyloid burden, hippocampal volume, or AD progression score. Additionally, a validation analysis was performed on a combined sample size of 536,190 participants.
Results
We show that the AD risk was not associated with genetic susceptibility of COVID-19 risk (OR = 0.98, 95% CI 0.81–1.19) and COVID-19 severity (COVID-19 hospitalization: OR = 0.98, 95% CI 0.9–1.07, and critical COVID-19: OR = 0.98, 95% CI 0.92–1.03). Genetic predisposition to COVID-19 is not associated with AD progression as measured by hippocampal volume, cortical amyloid beta load, and AD progression score. These findings were replicated in a set of 536,190 participants. Consistent results were obtained across models based on different GWAS summary statistics, MR estimators and COVID-19 definitions.
Conclusions
Our findings indicated that the genetic susceptibility of COVID-19 is not associated with the risk and progression of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
- Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL, USA.
- Department of Neuroscience, Development and Regenerative Biology, College of Sciences, The University of Texas at San Antonio, San Antonio, TX, USA.
Förderung
- NIA NIH HHS
- NCATS NIH HHS
- NIAAA NIH HHS
- NICHD NIH HHS
Zitieren
APA
Ding, P., Gurney, M., Perry, G., & Xu, R. (2023). Association of COVID-19 with Risk and Progression of Alzheimer’s Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-230632
Vancouver
Ding P, Gurney M, Perry G, Xu R. Association of COVID-19 with Risk and Progression of Alzheimer’s Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects. Journal of Alzheimer's Disease. 2023. doi:10.3233/jad-230632
BibTeX
@article{Ding2023,
author = {Ding, Pingjian and Gurney, Mark and Perry, George and Xu, Rong},
title = {Association of COVID-19 with Risk and Progression of Alzheimer’s Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects},
journal = {Journal of Alzheimer's Disease},
year = {2023},
doi = {10.3233/jad-230632}
}
EUVIMED